Limited sampling strategy for the estimation of systemic exposure to the protease inhibitor nelfinavir

Therapeutic Drug Monitoring

Volumn 27, Issue 5, 2005, Pages 571-575

  Regazzi, Mario B ^a   Tinelli, Carmine ^a   Villani, Paola ^a   Cusato, Maria ^a   Zucchi, Patrizia ^a   De Silvestri, Annalisa ^a   Briganti, Elena ^b   Roda, Rinaldo ^c   Sacchelli, Luca ^d   Gatti, Francesca ^e   Delle Foglie, Palma ^f   Nardini, Giulia ^g   Mori, Fernanda ^h   Castelli, Paula ⁱ   Testa, Lucia ^j   Maserati, Renata ^k  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^c S ANNA HOSPITAL   (Italy)

^d Maggiore Hospital   (Italy)

^e Maggiore Hospital   (Italy)

^f SANTA CHIARA HOSPITAL   (Italy)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h San Bartolo Hospital   (Italy)

ⁱ Ospedale Infermi   (Italy)

^j Gen Prov Hosp   (Italy)

^k S MARIA NUOVA HOSPITAL   (Italy)

more..

Author keywords

Area under the curve (AUC); Limited sampling strategy (LSS); Nelfinavir; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL PRACTICE; COMORBIDITY; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG EXPOSURE; DRUG MONITORING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMITED SAMPLING STRATEGY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEINASE INHIBITION; SYSTEMIC CIRCULATION; TREATMENT FAILURE; VALIDATION PROCESS; VIRUS RESISTANCE;

AREA UNDER CURVE; BLOOD SPECIMEN COLLECTION; DRUG MONITORING; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; NELFINAVIR;

EID: 26444466175     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000172996.87655.c8     Document Type: Article

References (11)

1. Aarnoutse RE, Shapiro JM, Boucher CAB, et al. Therapeutic drug monitoring. An aid to optimising response to antiretroviral drugs? Drugs. 2003;63:741-753.
2. De Maat MMR, Huitema ADR, Mulder JW, et al. Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care. Ther Drug Monit. 2003;25:367-373.
3. Acosta EP, Gerber JG, and the Adult Pharmacology Committee of the AIDS Clinical Trials Group. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retrovirus. 2002;18:825-834.
4. Gerber JG, Acosta EP. The potential role of therapeutic drug monitoring in the treatment of HIV infection. Ther Drug Monit. 2002;10:27-32.
5. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 2003;17:1157-1165.
6. Veldkamp AI, Van Heeswijk RPG, Mulder JW, et al. Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 non-nucleoside reverse transcriptase inhibitor nevirapine. Ther Drug Monit. 2001;23:606-611.
7. Mueller BU, Lewis LL, Yuen GJ, et al. Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 1998;42:3187-3192.
8. Wu EY, Wilkinson JM, Naret DG, et al. High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. J Chromatogr B. 1997;695:373-380.
9. + and HIV/HCV co-infected subjects. Antimicrob Agents Chemother. 2005;49:643-649.
10. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS. 2002;16:551-560.
11. Gerber JG. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. Clin Infect Dis. 2000;30:S123-S129.